검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | O6-Benzylguanine (O6-Benzylguanine) Keryx / AOI Pharmaceuticals, Inc.·Human Immunodeficiency Virus 1 Pos… ORR 4%·t½ 5 h |
|---|---|
Overview Program | O6-Benzylguanine |
Overview Company | Keryx / AOI Pharmaceuticals, Inc. |
Overview Modality | CGT |
Overview Target | Human Immunodeficiency Virus 1 Positive |
Overview Indication | Human Immunodeficiency Virus 1 Positive; Stage I Adult Hodgkin Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
PK/PD Half-life | 5 h |
Toxicology Major finding | O6-methylguanine-DNA methyltransferase inhibition leads to cellular senescence and vascular smooth muscle dysfunction.. Inhibiting O6-methylguanine-DNA methyltransferase (MGMT) is crucial for overcoming chemoresistance to alkylating agents, though its use is limited by myelosuppression. Beyond bone marrow, other adverse effects were not studied. Given chemotherapy-induced senescence in healthy tis… |
Clinical Primary efficacy | ORR 4% |
Clinical ORR | 4% |
Clinical Result source | ClinicalTrials.gov NCT00275002 |
Clinical Data Tier / Score | A · 7 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 5월 22일 (53일 전 · 갱신 권장) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | O6-Benzylguanine (O6-Benzylguanine) Keryx / AOI Pharmaceuticals, Inc.·Human Immunodeficiency Virus 1 Pos… ORR 4%·t½ 5 h |
|---|---|
Overview Program | O6-Benzylguanine |
Overview Company | Keryx / AOI Pharmaceuticals, Inc. |
Overview Modality | CGT |
Overview Target | Human Immunodeficiency Virus 1 Positive |
Overview Indication | Human Immunodeficiency Virus 1 Positive; Stage I Adult Hodgkin Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
PK/PD Half-life | 5 h |
Toxicology Major finding | O6-methylguanine-DNA methyltransferase inhibition leads to cellular senescence and vascular smooth muscle dysfunction.. Inhibiting O6-methylguanine-DNA methyltransferase (MGMT) is crucial for overcoming chemoresistance to alkylating agents, though its use is limited by myelosuppression. Beyond bone marrow, other adverse effects were not studied. Given chemotherapy-induced senescence in healthy tis… |
Clinical Primary efficacy | ORR 4% |
Clinical ORR | 4% |
Clinical Result source | ClinicalTrials.gov NCT00275002 |
Clinical Data Tier / Score | A · 7 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 5월 22일 (53일 전 · 갱신 권장) |
추천 비교
추천 비교